Florence Damond
Overview
Explore the profile of Florence Damond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Charpentier C, Berzow D, Le Hingrat Q, Kaiser R, Gomes P, Miranda A, et al.
Clin Infect Dis
. 2025 Mar;
PMID: 40071658
Human immunodeficiency virus type 2 (HIV-2) is an attenuated retroviral infection characterized by specific natural susceptibility to antiretroviral drugs and acquired resistance profiles. Based on the latest knowledge of phenotypic...
2.
Montrouge T, Bertine M, Peytavin G, Saint Joannis T, Bachelard A, De Truchis P, et al.
Clin Infect Dis
. 2024 Dec;
PMID: 39737782
Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with...
3.
Serris A, Ferre V, Le Hingrat Q, Bachelard A, Charpentier C, Exarchopoulos M, et al.
J Antimicrob Chemother
. 2024 Sep;
79(11):2932-2938.
PMID: 39287977
Introduction: Cabotegravir, an integrase strand transfer inhibitor, and rilpivirine, an NNRTI, constitute the first long-acting (LA), injectable, two-drug ART regimen approved for the maintenance of virological suppression in persons living...
4.
Joly V, Ferre V, Le Hingrat Q, Peytavin G, Cresta M, Charpentier C, et al.
Clin Infect Dis
. 2024 Sep;
PMID: 39283963
This retrospective study evaluated Bictegravir/FTC/TAF in 24 PWHIV, 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load < 40 copies/mL....
5.
Konu Y, Takassi E, Peytavin G, Dapam N, Damond F, Oumarou W, et al.
Clin Infect Dis
. 2024 May;
80(1):144-152.
PMID: 38748464
Background: Few data are available on the real-world efficacy of receiving tenofovir-lamivudine-dolutegravir (-DTG) as human immunodeficiencyvirus (HIV) treatment, particularly among young people in West Africa. Here, we evaluated pharmaco-virological outcomes...
6.
Bachelard A, Le Hingrat Q, Ferre V, Le M, Peytavin G, Damond F, et al.
Clin Infect Dis
. 2024 Apr;
78(4):1005-1010.
PMID: 38630945
We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved...
7.
Guiraud V, Bocobza J, Desmonet M, Damond F, Plantier J, Moreau G, et al.
J Clin Microbiol
. 2023 Jul;
61(8):e0061923.
PMID: 37458587
Immunoblots remain the gold standard for HIV-1/HIV-2 infection confirmation. However, their ability to differentiate HIV-1 from HIV-2 infection on an antigenically diversified HIV-1 and HIV-2 panel remain uncommon. We performed...
8.
Tchounga B, Bertine M, Damond F, Ferre V, Inwoley A, Boni S, et al.
PLoS One
. 2023 Mar;
18(3):e0283602.
PMID: 37000823
Objectives: This study aimed to confirm the co-infection with HIV-1 and HIV-2, among West African patients using in-house HIV type/group enzyme-immuno assays and molecular diagnosis. Design: A cross-sectional survey was...
9.
Charpentier C, Le Hingrat Q, Ferre V, Damond F, Descamps D
Viruses
. 2023 Feb;
15(2).
PMID: 36851754
Highly active antiretroviral (ARV) therapy has been used for many years, but the use in low- and middle-income countries of antiretroviral drugs with low genetic barrier to resistance, combined with...
10.
Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, et al.
AIDS
. 2022 Mar;
36(8):1055-1060.
PMID: 35262531
Objective: Treatment of multidrug-resistant HIV-2 is an emerging issue, because of the rapid selection of mutations at time of virological failure and the low number of antiretrovirals active on HIV-2....